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Abstract
Background:  The Brazilian consensus recommends a short-term treatment course with
clarithromycin, amoxicillin and proton-pump inhibitor for the eradication of Helicobacter pylori (H.
pylori). This treatment course has good efficacy, but cannot be afforded by a large part of the
population. Azithromycin, amoxicillin and omeprazole are subsidized, for several aims, by the
Brazilian federal government. Therefore, a short-term treatment course that uses these drugs is a
low-cost one, but its efficacy regarding the bacterium eradication is yet to be demonstrated. The
study's purpose was to verify the efficacy of H. pylori eradication in infected patients who presented
peptic ulcer disease, using the association of azithromycin, amoxicillin and omeprazole.
Methods: Sixty patients with peptic ulcer diagnosed by upper digestive endoscopy and H. pylori
infection documented by rapid urease test, histological analysis and urea breath test were treated
for six days with a combination of azithromycin 500 mg and omeprazole 20 mg, in a single daily
dose, associated with amoxicillin 500 mg 3 times a day. The eradication control was carried out 12
weeks after the treatment by means of the same diagnostic tests. The eradication rates were
calculated with 95% confidence interval.
Results: The eradication rate was 38% per intention to treat and 41% per protocol. Few adverse
effects were observed and treatment compliance was high.
Conclusion: Despite its low cost and high compliance, the low eradication rate does not allow
the recommendation of the triple therapy with azithromycin as an adequate treatment for H. pylori
infection.
Background
The eradication of Helicobacter pylori (H. pylori) in the
treatment of peptic ulcer is currently a world consensus
[1-6].
Several therapy courses have been employed in the eradi-
cation of the bacterium, with the use of drugs such as bis-
muth, clarithromycin, amoxicillin, furazolidone,
nitroimidazole compounds and proton pump inhibitors,
in assorted combinations [7-11].
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The search for low-cost and higher efficacy with fewer
adverse effects, that can allow higher compliance to H.
pylori eradication therapy, is a vital concern [12-16]. In
Brazil, where several particular situations are present, such
as higher bacterial resistance to antibiotics [17,18], special
health conditions [19] and low socioeconomic status of
the population [20,21], this task is even more delicate.
The macrolides are among the antibiotics that used alone,
present high rates of bacterium eradication, with few
adverse effects and simple regimen, especially clarithro-
mycin [22,23], although its previous use, similarly to
what occurs with nitroimidazole drugs, can determine
secondary bacterial resistance [24].
In Brazil, the triple therapy with amoxicillin and clarithro-
mycin, associated to a proton pump inhibitor for 7 days,
has attained good eradication rates [25], possibly because
this therapy has high compliance and presents low bacte-
rial resistance [18,26-28]. Hence, it has been recom-
mended as a first choice treatment in a national consensus
[5], although with a high cost (around US$75.00).
Azithromycin, a macrolide with a long term action
[29,30], is part of the assortment of drugs available for H.
pylori  treatment [31-34]. However, some studies have
shown low eradication rates [35,36]. In our country, a
study has shown good efficacy of this antibiotic when
associated with furazolidone [37]. Although another
study of our group, associating azithromycin with secni-
dazole in an ultra-fast treatment course, presented low
efficacy [38].
The Public Health services in our country do not provide
any eradication treatment for H. pylori, free of charge.
However, the federal government subsidizes, among
other drugs, the acquisition of omeprazole, azithromycin
and amoxicillin, through its Popular Pharmacy program
[39]. With the objective of offering a low-cost treatment to
eradicate the bacterium (in this case, at a cost of
US$10.00) we tested a 6-day drug therapy with azithro-
mycin associated with amoxicillin and omeprazole.
Methods
Setting
Sixty outpatients with H. pylori positive peptic ulcer, fol-
lowed at the Service of Gastroenterology of Clinics Hospi-
tal of the Medical School, University of São Paulo were
randomly invited to participate in the study. All patients
signed a free and informed consent form prior to enroll-
ment. The study was approved by the Ethics Committee of
the hospital.
Inclusion and exclusion criteria
The inclusion criteria were: peptic ulcer diagnosed by
upper digestive endoscopy, and H. pylori infection, con-
firmed by rapid urease test, histological analysis and the
Urea Breath Test (UBT).
The exclusion criteria were: age younger than 16 or older
than 90 years, chronic use of acetylsalicylic even at low
doses, or other anti-inflammatory drugs, previous use of
macrolides, use of antibiotics or chemotherapeutic drugs
in the 4 weeks prior to study enrollment, having compli-
cated peptic ulcer, pyloric stenosis, previous gastric sur-
gery, erosive esophagitis, to be pregnant or breastfeeding,
having consumptive diseases or not controlled renal,
heart or hepatic failure, having been previously treated for
H. pylori eradication or having participated in any other
clinical studies in the two months prior to the study
enrollment.
Study design
The eradication treatment was carried out with omepra-
zole 20 mg and azithromycin 500 mg in a single daily
dose taken in fasting condition in the morning, associated
with amoxicillin 500 mg, taken three times a day immedi-
ately after meals, for six days.
The adverse effects and the compliance were documented
on the first day after the end of the treatment. The type,
intensity and duration of the adverse effects were
recorded. The medication blisters were assessed and the
remaining tablets or capsules were counted.
Treatment control was carried out 10 to 12 weeks after the
end of treatment, when the UBT and an upper digestive
endoscopy done. Samples from corpus and antrum
mucosa were colleted to perform the rapid urease test and
histological analysis.
Patients were considered cured when they presented neg-
ative results in at least two of the performed tests and, in
case of discordant test results, a new UBT was performed
two months after the control.
The symptomatic patients were allowed to use antacid
medication after the drug therapy up to the time when the
eradication control tests were performed.
Statistical analysis
The statistical analysis was carried out with the SPSS pro-
gram, version 10.0 (SPSS Inc. USA).
The sample calculation was determined by means of a
descriptive study of one dichotomous variable, in which
the prevalence of peptic ulcer disease in the general popu-
lation was assumed to be 8% and the lower bacteriumBMC Gastroenterology 2008, 8:20 http://www.biomedcentral.com/1471-230X/8/20
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eradication efficacy was 75%. The eradication rates were
studied per intention to treat and per protocol. All of the
patients included in the study were considered for the
analysis of per intention to treat. The patients who took
most of the medication adequately and came back for the
control evaluation were considered for the per protocol
analysis. The 95% confidence interval was determined for
the eradication rates.
Results
The study group consisted of sixty patients. The character-
istics of the studied population are shown in Table 1.
Duodenal ulcers were present in 52% of the patients. Cig-
arette smoking was reported by 35%. Four patients not
return for the eradication control. One of these patients
withdrew the medication after only two days, due to the
presence of diarrhea. Adverse effects were reported by 20
of the 60 patients included in study (33%), being consid-
ered mild by 17 patients (28%), moderate by two patients
(3%) and severe by only one patient, who withdrew the
treatment. The most frequent adverse effects were diarrhea
(22%) and nausea (5%).
The bacterium eradication was attained by 23 of the 56
patients assessed: 41% per protocol (Table 2).
Discussion
In Brazil, the majority of the population depends on pub-
lic health services to have access to healthcare [40]. In
addition, part of the population that has private health
insurance or can afford private healthcare services,
depends on the government's subsidy or free medication
programs to obtain the drugs. Some healthcare programs
such as the tuberculosis [41], AIDS [42], as well as the dia-
betes or hypertension [43] warrant free medication to all
of the Brazilian population. Although it is a consensus
that the curative treatment of peptic ulcer disease depends
on the eradication of the H. pylori [44] and that the cost
benefit ratio is favorable regarding this approach [45], the
government does not provide any eradication strategy free
of charge through the public health system.
The country has characteristics of a developing country,
regarding the aspect of income distribution [20,21], as
well as the prevalence (quite high) of H. pylori infection
[46-49], with the bacterium being resistant to many anti-
biotics [18]. However, the treatment with a proton pump
inhibitor, amoxicillin and clarithromycin has reached
good eradication rates [25], close to those observed in
developed countries [50] and differently from those
observed with the association of proton pump inhibitor,
nitroimidazoles and clarithromycin [51,52], possibly due
to the primary resistance of H. pylori to these compounds
[17,18]. There are different packs of triple treatments in
the Brazilian market, associating a proton pump inhibi-
tor, amoxicillin and clarithromycin, presented in blisters
for daily use during 7 days of treatment, which favors
treatment compliance and control [53,54]. However, due
to its cost, it cannot be afforded by the majority of the
population.
In Brazil, peptic ulcer disease and gastric cancer represent
important causes of mortality [55,56] and thus, the eradi-
cation of H. pylori is desirable for all infected individuals.
Azithromycin has an in vitro bactericidal effect against H.
pylori [57] and this study assessed its administration in
association with amoxicillin for six days. As azithromycin,
omeprazole and amoxicillin are subsidized by the Brazil-
ian federal government [39], this treatment approach
could be a powerful and low-cost weapon for the treat-
ment of these diseases in our country. It is also notewor-
thy the pharmacokinetic characteristics of azithromycin
[58], which can provide a shorter treatment and favor the
patients' compliance. Mild and tolerable adverse effects
can be expected, similar to those observed with clarithro-
mycin therapy.
Several studies obtained good efficacy in H. pylori eradica-
tion with short-term triple therapy using azithromycin,
amoxicillin and a proton pump inhibitor [59-61]. Proba-
bly better efficacy can be achieved with a higher dose of
azithromycin [33].
The present study has indeed showed high compliance
and a few significant adverse effects; however, low eradi-
cation rates were observed. It is important to stress that, a
Table 1: Characteristics of the studied population.
Patients 60
Age (yrs) Mean 48
Median 47
Range 21 – 83
Sex Women 31 (52%)
Men 29 (48%)
Peptic ulcer risk Smokers 21 (35%)
NSAIDs* users 16 (27%)
Peptic ulcer type Gastric 24 (40%)
Duodenal 31 (52%)
Gastric + Duodenal 5 (8%)
NSAIDs* = Non-Steroidal Anti-Inflammatory Drugs
Table 2: Eradication rates.
Rate and percentage Confidence interval (95%)
Intention to treat 23/60 38% 51 – 26%
Per Protocol 23/56 41% 54 – 28%BMC Gastroenterology 2008, 8:20 http://www.biomedcentral.com/1471-230X/8/20
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macrolide use can probably decrease future treatment effi-
cacy, when these compounds are reutilized.
Although azithromycin is a macrolide that reaches high
concentration in plasma and in the gastric mucosa, the
low eradication rates can be explained by its low concen-
tration in the gastric juice [62]. It is noteworthy that a
study observed an eradication rate of 80% 30 days after
the treatment and 20% after 60 days, which suggests a
temporary suppression of the infection [30].
Conclusion
The short term therapy for H. pylori eradication using azi-
thromycin 500 mg and omeprazole 20 mg in a single
daily dose, associated with amoxicillin 500 mg three
times a day resulted in few adverse effects, and high com-
pliance with low costs. But low eradication rates observed
with this approach do not allow recommending it as an
alternative treatment.
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